Hubbry Logo
Asymptomatic inflammatory prostatitisAsymptomatic inflammatory prostatitisMain
Open search
Asymptomatic inflammatory prostatitis
Community hub
Asymptomatic inflammatory prostatitis
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Asymptomatic inflammatory prostatitis
Asymptomatic inflammatory prostatitis
Asymptomatic inflammatory prostatitis
View on Wikipedia
from Wikipedia
Asymptomatic inflammatory prostatitis
SpecialtyUrology

Asymptomatic inflammatory prostatitis is a painless inflammation of the prostate gland where there is no evidence of infection.[1] It should be distinguished from the other categories of prostatitis characterised by either pelvic pain or evidence of infection, such as chronic bacterial prostatitis, acute bacterial prostatitis and chronic pelvic pain syndrome (CPPS).[2] It is a common finding in men with benign prostatic hyperplasia.[3]

Signs and symptoms

[edit]

These patients have no history of genitourinary pain complaints, but leukocytosis is noted, usually during evaluation for other conditions.[1]

Diagnosis

[edit]

Diagnosis is through tests of semen, expressed prostatic secretion (EPS) or prostate tissue that reveal inflammation in the absence of symptoms.[4]

Treatment

[edit]

No treatment required. It is standard practice for men with infertility and category IV prostatitis to be given a trial of antibiotics and/or anti-inflammatories, although evidence of efficacy are weak.[5] Since signs of asymptomatic prostatic inflammation may sometimes be associated with prostate cancer, this can be addressed by tests that assess the ratio of free-to-total PSA. The results of these tests were significantly different in prostate cancer and category IV prostatitis in one study.[6]

Additional images

[edit]
  • Prostate, urethra, and seminal vesicles.
    Prostate, urethra, and seminal vesicles.
  • The arteries of the pelvis.
    The arteries of the pelvis.
  • Male pelvic organs seen from right side.
    Male pelvic organs seen from right side.

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Asymptomatic inflammatory prostatitis

View on Grokipedia
from Grokipedia
Asymptomatic inflammatory prostatitis (AIP), also known as (NIH) category IV , is a condition characterized by leukocyte infiltration and inflammation in the prostate gland without any associated symptoms in the genitourinary tract. Unlike other forms of , AIP does not cause pain, urinary difficulties, or , and it is typically nonbacterial in nature. AIP is often diagnosed incidentally during routine medical tests for unrelated issues, such as prostate biopsies, , or evaluation of elevated (PSA) levels. Diagnosis relies on laboratory findings, including the presence of in expressed prostatic secretions, post-prostate massage urine, or prostate tissue samples, without evidence of infection. The exact remains unclear, though it may involve immune-mediated responses or undetected pathogens, and it is not linked to acute bacterial infection. Prevalence studies indicate that AIP is relatively common among men, with rates ranging from 21.1% in populations to 32–44% in prostate biopsy cohorts and up to 77.6% in men with histologic (BPH). Despite its frequency, AIP generally requires no treatment due to the absence of symptoms and lack of complications, though it can contribute to elevated PSA levels, potentially leading to unnecessary concerns about . Emerging research suggests a possible role in the progression of BPH and through repeated cycles of tissue inflammation, destruction, and remodeling.

Introduction and Classification

Definition and characteristics

Asymptomatic inflammatory prostatitis is a subtype of characterized by evidence of , typically identified through histological examination or analysis of prostatic fluids, in the complete absence of clinical symptoms such as , urinary disturbances, or genitourinary complaints. This condition reflects an inflammatory process confined to the without overt clinical manifestations, distinguishing it from symptomatic forms of . Key diagnostic hallmarks include leukocytospermia, defined by the as more than 1 × 10^6 per milliliter of , or the presence of inflammatory cells—commonly exceeding 10 per —in expressed prostatic secretions (EPS). Alternatively, it may be confirmed histologically via prostate biopsy showing leukocyte infiltration in glandular tissue. Unlike bacterial , does not require evidence of infection; the focus is solely on inflammatory markers, and the condition is often non-bacterial in nature. It is typically silent, with no progression to symptomatic disease or complications in most cases, rendering it clinically insignificant unless discovered incidentally. This entity was first formalized as a distinct category in the late 1990s through histopathological studies and consensus efforts that refined classifications, highlighting inflammation in asymptomatic individuals during evaluations for other conditions. It aligns with category IV in the (NIH) classification system for .

Role in NIH classification

The (NIH) established a standardized classification system for syndromes in 1995 through an international consensus workshop, dividing the condition into four distinct categories to address prior diagnostic inconsistencies and improve research and clinical consistency. Category I encompasses acute bacterial , characterized by sudden onset with systemic symptoms and positive bacterial cultures; Category II includes , involving recurrent urinary tract infections with documented prostate involvement; Category III covers chronic /chronic syndrome (CP/CPPS), which is the most common form and subdivided into inflammatory (IIIA) and non-inflammatory (IIIB) subtypes based on the presence of leukocytes in prostatic secretions; and Category IV designates asymptomatic inflammatory , marked by prostatic inflammation without any associated symptoms. Category IV, asymptomatic inflammatory prostatitis, is specifically defined by the presence of in expressed prostatic secretions, , or prostatic tissue samples, but in the complete absence of pain, urinary symptoms, or that define the other categories. This category contrasts sharply with the symptomatic ones (I-III), as it is typically identified incidentally during evaluations for unrelated conditions, such as elevated (PSA) levels or prostate biopsies for , without requiring treatment unless complications arise. The 1995 NIH framework introduced this category to recognize inflammatory changes in the that do not manifest clinically, thereby refining the to exclude such cases from symptomatic diagnoses and highlighting the need for better understanding of subclinical inflammation. Since its inception, the NIH classification has undergone refinements through the 2010s, primarily in the evaluation of Category III with the development of tools like the NIH Chronic Symptom Index (NIH-CPSI) for symptom assessment, but Category IV has seen no major structural changes by 2025. Updates have incorporated biomarkers such as PSA, noting that asymptomatic inflammation can elevate serum PSA levels similarly to , prompting its consideration in diagnostic algorithms to avoid unnecessary biopsies. However, the core definition and role of Category IV remain anchored in the original consensus, emphasizing its utility in epidemiological studies and incidental findings rather than altering its asymptomatic criterion.

Epidemiology

Prevalence and incidence

Asymptomatic inflammatory prostatitis, classified as (NIH) category IV, is frequently detected incidentally during evaluations for other conditions. In men undergoing prostate biopsies primarily for elevated (PSA) levels or , the prevalence ranges from 21% to 32%, with one study reporting 32.2% among 227 asymptomatic men presenting for screening. In semen analyses, the condition may be indicated by elevated counts, with one study reporting up to 19% prevalence in young men (mean age 18.9 years) using a lower diagnostic threshold of greater than 0.2 × 10^6 per milliliter, though figures vary and direct assessment in evaluations is limited. Due to its asymptomatic nature, true incidence rates are challenging to track through routine , but studies provide insight into its occurrence in the general population. Histological examinations reveal prostatic inflammation consistent with category IV in 20-44% of prostates from men over 50 years old, with some series showing rates as high as 70% in older age groups (including a 2024 estimate of about 70% at ), often coexisting with . Estimates from studies in the 2000s, such as those involving and cohorts, have remained relatively stable. Demographic trends indicate that prevalence increases with age, as accumulates over time in prostatic tissue. Rates appear similar across major ethnic groups in Western populations, with chronic observed in approximately 78% of examined prostates regardless of race, though data from non-Western regions remain limited and potentially underreported due to fewer and studies.

Associated populations and risk factors

Asymptomatic inflammatory prostatitis is commonly identified incidentally in men undergoing prostate biopsies for elevated (PSA) levels or during evaluations. in these groups ranges from 11% to 42%, reflecting its frequent discovery in histopathological examinations unrelated to symptomatic complaints. It is particularly prevalent in men with (BPH), with rates up to 77.6% in histologic BPH cohorts. In subfertile males, the condition is often linked to leukocytospermia (elevated in ), with leukocytospermia occurring in up to 30% of infertile men and contributing to reduced fertility parameters. Risk factors for asymptomatic inflammatory prostatitis include advancing age, with prevalence increasing progressively from 17.2% in men aged 19–29 years to 26.3% in those aged 60 years and older; age ≥40 years confers an adjusted of 1.35. The condition is also associated with (BPH), as chronic prostate inflammation may exacerbate age-related glandular enlargement. Possible contributing factors encompass prior urinary tract infections (UTIs) or pelvic trauma, which can initiate subclinical inflammatory processes, though direct causal evidence specific to the asymptomatic form remains limited. No strong genetic predispositions have been established through large-scale studies. Some cohort investigations suggest a mild association with , potentially due to systemic inflammatory effects, but others report no significant link after adjusting for confounders. Protective factors are not definitively identified, but data from 2010s cohort studies indicate lower rates of prostatitis-related , including forms, among circumcised men, possibly attributable to reduced ascending urinary infections from foreskin-related issues (odds ratio for chronic prostatitis/chronic syndrome in uncircumcised men with redundant prepuce: up to 2.91).

Pathophysiology

Etiology

The etiology of inflammatory remains poorly understood and is considered multifactorial, with no single definitive cause identified. It is classified as a nonbacterial form of (NIH Category IV), characterized by leukocyte infiltration in prostatic secretions or tissue without evidence of active infection or symptoms. Potential triggers include both infectious and non-infectious factors, often discovered incidentally during evaluations for other conditions like or prostate biopsies. Infectious etiologies are implicated in a minority of cases, though most are culture-negative. Low-grade or occult bacterial involvement, such as remnants of common uropathogens like , has been suggested based on histopathological findings, but routine cultures fail to isolate organisms in the vast majority of patients. Viral infections may also contribute to subclinical , potentially leading to repeated cycles of tissue damage and repair, though evidence is limited and viral pathogens are rarely detected. Fungal or other atypical infections are considered exceptional and not primary drivers. Non-infectious causes predominate in proposed mechanisms, including autoimmune responses where the targets prostate-specific antigens, resulting in chronic low-level without overt symptoms. Chemical from reflux of sterile urine into prostatic ducts can provoke inflammatory cascades, exacerbated by conditions like or voiding dysfunction that impair drainage. Additionally, systemic factors such as have been associated, with dyslipidemia and promoting prostate through and altered . Despite these associations, exact triggers are unclear, and no causal pathogens have been confirmed as of 2025. Research from the has highlighted potential roles for in prostatic fluid or semen, with altered bacterial diversity (e.g., reduced and increased Firmicutes or Proteobacteria) observed in affected individuals compared to controls, possibly linking gut or urogenital imbalances to inflammatory initiation; however, causality remains unestablished and requires further validation.

Inflammatory mechanisms

In asymptomatic inflammatory prostatitis (NIH category IV), the primary cellular process involves the infiltration of leukocytes, including neutrophils and lymphocytes, into the prostate stroma and acini, as evidenced by histological examinations and analysis of prostatic secretions showing elevated counts. This infiltration contributes to localized inflammation without eliciting symptomatic responses. Additionally, prostatic fluid exhibits increased levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which mediate the recruitment and activation of these immune cells. Tissue changes in this condition are characterized by mild glandular disruption, including focal and epithelial alterations, but notably without significant or extensive stromal remodeling. Unlike symptomatic forms of , such as chronic pelvic pain syndrome, asymptomatic inflammatory prostatitis lacks nerve sensitization, preventing the transmission of pain signals despite the presence of inflammatory mediators. At the molecular level, is driven by the upregulation of genes associated with the pathway, which promotes the transcription of pro-inflammatory factors and sustains leukocyte activity within the . Recent studies have further highlighted the role of , with elevated detected in , leading to cellular damage and amplification of inflammatory cascades in affected individuals.

Clinical Presentation

Absence of symptoms

Asymptomatic inflammatory prostatitis, classified as (NIH) Category IV, is defined by the presence of prostatic inflammation without any associated clinical symptoms. Unlike NIH Category III chronic prostatitis/chronic syndrome, which involves persistent or discomfort lasting at least three months along with potential urinary or sexual issues, individuals with Category IV experience no , , ejaculatory discomfort, or . This absence of genitourinary tract symptoms distinguishes it as a silent condition, with no reported irritative, obstructive, or storage urinary problems. The lack of symptoms in this condition arises primarily because the inflammation is localized to the prostate gland and does not extend to affect surrounding structures such as the or neural pathways that would otherwise trigger pain or voiding disturbances. Prostatic fluids may contain and proinflammatory cytokines like tumor factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), yet these markers do not correlate with symptomatic manifestations or elicit a perceptible response. Additionally, there are no systemic signs, such as fever or , further underscoring the confined nature of the inflammatory process. Patients with asymptomatic inflammatory prostatitis typically remain entirely unaware of the condition, as it produces no discernible impact on daily life or well-being. Diagnosis occurs incidentally during evaluations for unrelated issues, such as elevated levels, assessments, or prostate biopsies, where is detected in seminal fluid, expressed prostatic secretions, or tissue samples. This silent profile means affected individuals do not seek medical attention for prostatitis-related complaints, and the condition is often identified only through routine or targeted testing.

Contexts of incidental discovery

Asymptomatic inflammatory prostatitis is most frequently identified as an incidental finding during prostate biopsies performed for , often prompted by elevated (PSA) levels. In such procedures, histological examination reveals prostatic inflammation in a substantial proportion of cases, with studies reporting rates ranging from 40% to over 70% among men without prior symptoms of . For instance, the Medical Therapy of Prostatic Symptoms (MTOPS) trial found inflammatory findings in 45% of biopsy samples, while the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial reported 77.6%. Another key setting for discovery is conducted as part of evaluations, where leukocytospermia—defined as more than 1 million per milliliter of —serves as a marker for underlying prostate . This feature is noted in 10-20% of samples from infertile men, though its direct impact on fertility remains debated in the literature. The condition may also emerge incidentally during other reproductive or urological assessments, such as post-vasectomy analyses to confirm or routine evaluations in older men for or . In these contexts, is detected through histopathological review or seminal fluid examination without targeted screening for itself. No routine screening is recommended for asymptomatic inflammatory prostatitis due to its lack of clinical symptoms and unclear prognostic implications.

Diagnosis

Diagnostic criteria

The diagnosis of asymptomatic inflammatory prostatitis, classified as National Institutes of Health (NIH) Category IV prostatitis, requires the identification of prostatic inflammation in the absence of genitourinary symptoms or evidence of bacterial infection. According to the NIH consensus classification established in 1999, this condition is confirmed by the presence of (leukocytes) exceeding 10 per in expressed prostatic secretions (EPS) or post-massage urine (VB3); greater than 1 × 10^6 leukocytes per mL in ; or inflammatory infiltrates in prostatic tissue obtained via , without any clinical symptoms such as pain, urinary issues, or . To exclude bacterial prostatitis, cultures of , EPS, or must be negative for pathogenic organisms, ensuring the is non-infectious. If a has a of prior genitourinary symptoms, these must have fully resolved, distinguishing the condition from resolving acute or chronic bacterial forms. Prostate biopsy provides histological confirmation of , particularly for incidental findings during evaluations for elevated prostate-specific antigen (PSA) or other prostate conditions, as noted in the 2024 European Association of Urology (EAU) guidelines on urological s. However, it is not routinely recommended due to risks such as . PSA elevation alone is insufficient for diagnosis without corroborating evidence of , as it lacks specificity and may stem from other causes.

Methods and tests

Diagnosis of asymptomatic inflammatory prostatitis primarily relies on laboratory analysis of prostatic fluids and, when indicated, histopathological examination of prostate tissue. Fluid-based tests involve collecting expressed prostatic secretion (EPS) through gentle digital rectal massage of the , followed by immediate analysis for the presence of leukocytes using light . Alternatively, post-massage (the third voided specimen, or VB3) is obtained after the massage and examined similarly via to detect inflammatory cells originating from the . Semen analysis, collected via after 2-7 days of abstinence, can also be performed with microscopic for leukocytes (>1 × 10^6 per mL), providing another avenue for fluid assessment in contexts such as evaluations. Biopsy methods for confirming typically employ transrectal -guided needle of the , where multiple cores are systematically sampled from different prostate zones under and visualization. The obtained tissue samples are then processed for histopathological examination, involving hematoxylin and eosin staining to identify and characterize inflammatory infiltrates within the prostatic stroma or acini. This procedure is reserved for cases where fluid analysis is inconclusive or when evaluating elevated levels or abnormal digital rectal exam findings. Adjunctive tests include the digital rectal examination (DRE), performed with a gloved, lubricated finger inserted into the rectum to palpate the for size, consistency, and any nodularity, though tenderness is generally absent in asymptomatic cases. Unnecessary imaging, such as (MRI), is avoided unless there is suspicion of or other structural abnormalities, as routine use does not contribute to the diagnosis of inflammatory .

Management and Treatment

General approach

The general approach to managing asymptomatic inflammatory prostatitis emphasizes a conservative strategy, as the condition is characterized by prostate inflammation without associated symptoms or evidence of infection. is the cornerstone, with no active intervention required in the absence of symptoms; regular follow-up is reserved for cases linked to concerns or elevated (PSA) levels necessitating monitoring. This approach aligns with urological consensus, which prioritizes avoiding unnecessary treatments to prevent antibiotic resistance and potential harm. Patient education plays a central in care, informing individuals about the benign, self-limiting nature of the condition and reassuring them of no immediate health risks. Discussions should address any implications, recommending lifestyle measures such as adequate hydration to support if relevant. Major guidelines recommend against routine use, focusing instead on confirming the and excluding other underlying conditions like bacterial or . In select scenarios, such as when the condition is discovered incidentally during evaluations for elevated PSA or , brief consideration may be given to targeted interventions if indicated, though these remain exceptional.

Specific interventions if indicated

In instances of asymptomatic inflammatory prostatitis associated with leukocytospermia that impairs and , nonsteroidal drugs (NSAIDs) may be employed to mitigate and enhance parameters. Studies have shown efficacy of certain COX-2 inhibitors in resolving leukocytospermia and improving sperm parameters, though due to safety concerns, other NSAIDs are preferred. Similarly, antioxidants like have been evaluated in clinical trials for oxidative stress-related , including cases linked to prostatic , with a randomized double-blind placebo-controlled study showing significant improvements in following 300 mg twice-daily oral administration for three months. If bacterial is identified during diagnostic evaluation (indicating rather than true AIP), such as fluoroquinolones (e.g., or levofloxacin) are indicated for targeted eradication, typically administered for 4-6 weeks based on susceptibility testing. In the context of prostate , short-term therapy may be prescribed if is accompanied by signs of acute bacterial involvement, though routine use is limited to confirmed to avoid unnecessary exposure. Emerging therapies, including low-intensity (Li-ESWT), have been investigated in 2024 pilot studies primarily for symptomatic chronic , demonstrating safety and potential effects through improved tissue , though these remain non-standard and have no established role in asymptomatic cases as of 2025.

Prognosis and Complications

Long-term outcomes

Asymptomatic inflammatory prostatitis, classified as (NIH) category IV prostatitis, generally follows a benign natural history characterized by persistence without progression to symptomatic forms in most affected individuals. Cohort studies indicate that this condition remains clinically silent over extended periods, with no evidence of evolving into acute or or chronic pelvic pain syndrome. Histological inflammation may continue indefinitely but does not typically lead to structural changes that impair prostate function or . Resolution of the inflammatory process occurs spontaneously in some cases, though persistent low-grade is more common without clinical consequences. There is no established increased risk of progression to symptomatic , supporting a approach rather than active intervention. Factors influencing resolution remain unclear but may include underlying immune modulation or incidental discovery during evaluations for unrelated conditions like elevated PSA. For monitoring, annual PSA assessments are recommended in cases detected via prostate biopsy, particularly if initial levels were elevated, to confirm ongoing stability. Routine or invasive follow-up is not indicated, as long-term outcomes show no progression warranting such measures. While potential associations with other prostatic conditions exist, the isolated trajectory of asymptomatic inflammatory prostatitis remains favorable.

Potential associations and implications

Asymptomatic inflammatory prostatitis has been associated with through mechanisms involving , which damages sperm DNA and impairs motility and viability. generated by prostatic inflammation lead to in sperm membranes and fragmentation of sperm DNA, contributing to reduced fertility potential. Studies indicate that leukocytospermia, often linked to such inflammation, affects 10-20% of men, with genital tract inflammation, including , identified in 5-12% of infertility cases. Research suggests a possible role in the progression of (BPH) and the development of (LUTS). Repeated cycles of inflammation, tissue destruction, and remodeling in the prostate may contribute to structural changes that exacerbate BPH over time. The relationship between asymptomatic inflammatory prostatitis and remains controversial, with higher prevalence of inflammation observed in biopsies adjacent to cancerous tissue, but no established causal role. Meta-analyses accounting for detection bias show only a weak , with odds ratios reduced to approximately 1.16 after adjustments, suggesting that apparent links may stem from increased screening in symptomatic individuals rather than direct causation. Recent studies from 2024 further support no causal effect of prostatitis on development. This condition can also elevate (PSA) levels, potentially leading to unnecessary prostate biopsies in otherwise healthy men. Asymptomatic inflammation accounts for PSA elevations in a significant portion of cases within the diagnostic gray zone, with antibiotic therapy normalizing PSA in 20-30% of affected patients and thereby avoiding invasive procedures. No confirmed associations exist with or autoimmune disorders, as comprehensive reviews of do not identify such links for the asymptomatic subtype.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC3202001/
  2. https://www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems/prostatitis-inflammation-prostate
  3. https://www.mayoclinic.org/diseases-conditions/prostatitis/symptoms-causes/syc-20355766
  4. https://my.clevelandclinic.org/health/diseases/15319-prostatitis
  5. https://pubmed.ncbi.nlm.nih.gov/19192937/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC5717984/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC3742742/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC7673826/
  9. https://pubmed.ncbi.nlm.nih.gov/16209120/
  10. https://pubmed.ncbi.nlm.nih.gov/29264225/
  11. https://pubmed.ncbi.nlm.nih.gov/10422990/
  12. https://www.aafp.org/pubs/afp/issues/2010/0815/p397.html
  13. https://www.racgp.org.au/afp/2013/april/prostatitis
  14. https://pubmed.ncbi.nlm.nih.gov/10443716/
  15. https://www.merckmanuals.com/professional/multimedia/table/nih-consensus-classification-system-for-prostatitis
  16. https://www.auanet.org/guidelines-and-quality/guidelines/male-chronic-pelvic-pain
  17. https://pubmed.ncbi.nlm.nih.gov/12544313/
  18. https://pubmed.ncbi.nlm.nih.gov/18455767/
  19. https://pubmed.ncbi.nlm.nih.gov/25012523/
  20. https://www.ncbi.nlm.nih.gov/books/NBK599550/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC2292121/
  22. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0071298
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC5641057/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC8218447/
  25. https://digitalcollections.ohsu.edu/record/528/files/529_etd.pdf?ln=en
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC4215657/
  27. https://emedicine.medscape.com/article/785418-overview
  28. https://www.sciencedirect.com/science/article/pii/S1879522617300374
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC11087208/
  30. https://emedicine.medscape.com/article/456165-overview
  31. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1488732/full
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC5300850/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC6149977/
  34. https://www.mdpi.com/2072-6694/15/12/3110
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC3591463/
  36. https://www.mdpi.com/2077-0383/13/10/2841
  37. https://www.who.int/publications/i/item/9789240030787
  38. https://www.merckmanuals.com/professional/genitourinary-disorders/benign-prostate-disease/prostatitis
  39. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-Infections-2024.pdf
  40. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695374/
  41. https://bpac.org.nz/2023/prostatitis.aspx
  42. https://uroweb.org/guidelines/urological-infections
  43. https://www.mdpi.com/2673-4397/4/2/4
  44. https://www.rbmojournal.com/article/S1472-6483(10)61641-0/pdf
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC5209556/
  46. https://www.aafp.org/pubs/afp/issues/2016/0115/p114.html
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC5783704/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC11449405/
  49. https://www.storzmedical.com/en/disciplines/literature-database-blog/database-cpps-ipp-ed/joe-k-c-lee-et-al-2023/
  50. https://pubmed.ncbi.nlm.nih.gov/11025702/
  51. https://journalofethics.ama-assn.org/article/prostatitis-prevalence-classification-and-treatment/2006-11
  52. https://www.mdpi.com/2218-1989/15/4/267
  53. https://aacrjournals.org/cebp/article/28/10/1594/71744/A-Systematic-Review-and-Meta-analysis-of
  54. https://www.nature.com/articles/s41598-024-76355-4
Add your contribution
Related Hubs
User Avatar
No comments yet.